MRD testing will be a part of future AML clinical trials

One big development in clinical trial design in acute myeloid leukemia (AML) is the inclusion of measurable residual disease (MRD) testing. In this interview, Christopher Hourigan, MD, DPhil, of the N... Author: VJHemOnc Added: 07/04/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts